Souhaitez-vous accéder aux communiqués récents ?

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in...

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical...

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -  - Positions Humacyte to advance discussions with corporate partners regarding international and...

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success...

- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C.,...

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for a...

- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company’s leadership team to expand...

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...